Resources
Read the latest publications on our technology and applications.
Drug Type
- Small Molecule/Tyrosine Kinase Inhibitors
- Adoptive Cell Therapies
- Antibody Dependent Cellular Cytotoxicity
- Checkpoint Inhibitors
- Cell Therapies
- Antibody Drug Conjugates
- Other
Cancer Type
- Lung
- Kidney
- Brain
- NSCLC
- HNSCC
- Renal
- Colorectal
- Bladder
- Other
Need Help?
Contact Us for support
May 11, 2021
STING Application Note
![resource1 resource1](https://www.nilogen.com/wp-content/uploads/2021/05/STING-App-note-image.png)
May 10, 2021
Benefits of Tumoroids for Oncology R&D – Whitepaper
![resource1 resource1](https://www.nilogen.com/wp-content/uploads/2021/03/0001-scaled.jpg)
May 10, 2021
Studying the Mechanism of Action of Tumor Immune Cells – Application Note
![resource1 resource1](https://www.nilogen.com/wp-content/uploads/2021/05/MoA-app-note-image.png)
Jun 22, 2020
Employing ex vivo 3D-ScreenSM technology for the development of rational combinations of immune-oncology drugs in tumor organoids of fresh patient tissue
![resource1 resource1](https://www.nilogen.com/wp-content/uploads/2020/06/Employing-ex-vivo3D-ScreenSMtechnology-for-the-development-of-rational-combinations-of-immuno-oncology-drugs-in-tumor-organoids-of-fresh-patient-tissue-1-1.jpg)
Jun 22, 2020
Optimization of checkpoint inhibitor-TKI combinations in renal cell carcinoma using an ex vivo 3D tumor organoid model of fresh patient tissue with intact TME
![resource1 resource1](https://www.nilogen.com/wp-content/uploads/2020/06/Optimization-of-checkpoint-inhibitor-TKI-combinations.jpg)